EATG » PARADIGM: A collaborative initiative on patient engagement kicks-off

PARADIGM: A collaborative initiative on patient engagement kicks-off

PARADIGM (Patients Active in Research and Dialogues for an Improved Generation of Medicines), a new initiative regarding patient engagement in research and development of medicines, was launched this week during the first Open Forum on Patient Engagement in Brussels. The event was organised in collaboration with , the European Patients’ Academy (EUPATI) and Patient Focused Medicine Development (PFMD).  The consortium of partners had the opportunity to meet face-to-face and discuss about the structure, purpose and decision-making bodies of the project. The achievements in the field of patient engagement stemming from EUPATI and PFMD were highlighted as a starting platform to build upon.

 

One of the first activities that will kick-off in May is an online survey to assess the needs and expectations of the different stakeholders (patients, patient organisations, caregivers, pharmaceutical industry, researchers, regulators and HTA bodies). The findings of the survey will serve as a basis for the development of a set of practical tools on patient engagement. The EATG will seek to provide the experience of the patients through its membership.

 

You can find the official press release about the meeting here.

 

 

About the project:

The EATG is involved in a new pan-European project called PARADIGM: Patients Active in Research and Dialogues for an Improved Generation of Medicines. The project started on 1 March 2018 and ends in August 2020 and brings together a multi-stakeholder consortium of 34 partners lead by the European Patients’ Forum (EPF) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). PARADIGM is financed by the Innovative Medicines Initiative (IMI). The aim of the project is to provide a framework that allows structured, meaningful, sustainable and ethical patient engagement throughout three key decision-making points of the development of medicinal products: (i) the research priority setting; (ii) the design of clinical trials and (iii) the early dialogues with regulators and HTA bodies. The work builds upon previous initiatives such the European Patients’ Academy (EUPATI) and Patient Focused Medicine Development (PFMD).

 

The EATG plays an important role in the project as a whole, and specifically in Work Package 4, which aims to build on and extend previous knowledge in order to develop a new set of concrete tools on patient engagement addressing key stakeholder groups (patients, patient organisations, industry, regulators and HTA bodies). These tools (guidance, templates, webinars etc.) will be made available on an online platform (toolbox).

Share on FacebookTweet about this on TwitterShare on Google+Pin on PinterestShare on LinkedIn
News categories: Scientific research